# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian epithelial cancer

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 2361 results.
Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer
Status: Not yet recruiting
Last Changed: Nov 01, 2019
First Received: Jul 18, 2017
Disease(s): Ovarian Epithelial Cancer
Intervention(s): Cytoreductive surgery combined with HIPEC, Chemotherapy and bevacizumab (CT-BEV)
Locations: Centre Hospitalier Universitaire Jean Minjoz, Besançon, France
Centre Hospitalier Universitaire Jean Minjoz, Besançon, France
Centre Oscar Lambret, Lille, France
CHRU Claude Huriez, Lille, France
Centre Léon Bérard, Lyon, France
... and 18 other locations.
Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer
Status: Active, not recruiting
Last Changed: Mar 18, 2020
First Received: Mar 13, 2017
Disease(s): Ovarian Epithelial Cancer
Intervention(s): SPL-108
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Columbia University Medical Center, New York, New York, United States
Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
Status: Completed
Last Changed: Mar 27, 2020
First Received: Mar 20, 2015
Disease(s): Ovarian Epithelial Cancer Recurrent
Intervention(s): Trabectedin and Pegylated Liposomal Doxorubicin
IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer
Status: Completed
Last Changed: May 01, 2012
First Received: May 01, 2012
Disease(s): Ovarian Epithelial Cancer Recurrent
Intervention(s): HIPEC
Docetaxel and Oxaliplatin in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
Status: Unknown status
Last Changed: Jul 24, 2008
First Received: Jan 12, 2004
Disease(s): Ovarian Cancer
Intervention(s): docetaxel, oxaliplatin
Locations: Intercommunal Hospital, Montfermeil, France
Hopital Saint Antoine, Paris, France
Hopital Tenon, Paris, France
Polyclinique De Courlancy, Reims, France
C.H. Senlis, Senlis, France
... and 1 other locations.
Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France
Status: Active, not recruiting
Last Changed: Aug 23, 2018
First Received: Dec 05, 2016
Disease(s): Ovarian Epithelial Cancer
Intervention(s): Patient with ovarian epithelial cancer
Locations: Calvados registry, Caen, France
Côte d'or registry, Dijon, France
Oveval, Lyon, France
A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer
Status: Completed
Last Changed: Jan 03, 2014
First Received: Jan 03, 2014
Disease(s): Ovarian Epithelial Cancer Recurrent
Intervention(s): Carboplatin, Docetaxel
Locations: Aalborg University Hospital, Aalborg, Denmark
Herlev University Hospital, Copenhagen, Denmark
Tampere University Hospital, Tampere, Finland
Norwegian Radium Hospital, Oslo, Norway
Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
Status: Completed
Last Changed: Nov 19, 2019
First Received: Nov 28, 2012
Disease(s): Ovarian Epithelial Cancer Recurrent
Intervention(s): bevacizumab and trabectedin, bevacizumab, trabectedin and carboplatin
Locations: Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
AO Fatebenefratelli e Oftalmico, Milano, Italy
Istituto Europeo di Oncologia, Milan, Italy
Azienda Ospedaliera S. Gerardo, Monza, Italy
Istituto Oncologico Veneto, Padova, Italy
... and 3 other locations.
Safety of Active Immunotherapy in Subjects With Ovarian Cancer
Status: Unknown status
Last Changed: Mar 01, 2013
First Received: Oct 20, 2011
Disease(s): Ovarian Epithelial Cancer
Intervention(s): Procure, Procure
Locations: Hospital Landeskrankenhaus Innsbruck, Innsbruck, Austria
Hospital Korneuburg, Korneuburg, Austria
Hospital Barmherzigen Schwestern, Linz, Austria
Semelweis University, Budapest, Hungary
National Oncology Institute, Budapest, Hungary
... and 1 other locations.
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
Status: Completed
Last Changed: Dec 28, 2017
First Received: Feb 15, 2008
Disease(s): Ovarian Cancer
Intervention(s): Fulvestrant
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States